指南与共识老年精神精神分裂症与精神病性障碍会诊联络精神医学

痴呆患者基层医疗中抗精神病药处方对英国指南的依从性队列研究

Antipsychotic prescriptions in people with dementia in primary care: a cohort study investigating adherence of dose and duration to UK clinical guidelines.
指南 / 共识 · Lancet Psychiatry · 2025-01-01

该回顾性队列研究利用英国IQVIA医学研究数据库,纳入2000至2023年间首次接受抗精神病药处方的60-85岁痴呆患者9819例,评估用药剂量与疗程对NICE指南的依从性。

要点

  • 首次抗精神病药治疗中位疗程7个月,远超NICE指南1-3个月推荐。

核心结论

  • 痴呆患者抗精神病药处方在疗程和剂量两方面均与现行NICE指南不一致。
  • 超过半数停药患者随后重启抗精神病药治疗。
  • 指南与真实世界处方之间存在持续差距,需优先考虑安全性和以人为中心照护的干预。

研究设计与样本

  • 回顾性队列研究,使用英国IQVIA医学研究数据库纵向基层医疗数据。
  • 排除既往1年以上有抗精神病药记录者及社会剥夺信息缺失者;采用等待时间分布法(80%到达密度,59天)划分治疗 episode。

关键数值与推荐

  • NICE推荐:痴呆患者若启用抗精神病药,应使用最低剂量、最短时间(1-3个月)。
  • 研究以既定最低有效剂量等效性将日剂量分为低、中、高三个等级。

临床怎么用

  • 基层医疗中应定期审查痴呆患者抗精神病药的疗程与剂量,及时尝试减量或停药。
  • 对停药患者需监测症状复发风险,但重启治疗时应重新评估适应证与剂量。
  • 处方决策应结合非药物干预和以人为中心的照护目标。

局限性

  • 种族数据不可用。
  • 研究为回顾性设计,依赖基层医疗记录,可能存在处方信息不完整或错分。
  • 未报告剂量分类的具体等效阈值及等待时间分布法的详细参数设定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the UK, it is recommended by the National Institute for Health and Care Excellence (NICE) that if antipsychotics are initiated in people living with dementia, treatment should be at the lowest dose for the shortest time possible (1-3 months). In this study, we aimed to investigate how dose and duration of antipsychotic medication adhere to UK clinical guidelines and explore treatment restart details in those who stop treatment. METHODS: We did a retrospective cohort study using longitudinal UK primary care data from the IQVIA Medical Research Database. We included people living with dementia aged 60-85 years who received their first antipsychotic prescription between Jan 1, 2000, and Dec 31, 2023. Individuals with any previous antipsychotic prescriptions in their records more than 1 year before a dementia diagnosis and those who had missing social deprivation information were excluded from the study. Duration of first and subsequent antipsychotic treatment episodes, medication dosage, and treatment discontinuation and reinitiation rates were investigated. Duration and discontinuation were defined by grouping consecutive prescriptions into treatment episodes using the waiting time distribution method (80% inter-arrival density, 59 days). Daily doses were derived from strength and frequency information and categorised as low or moderate or high based on established minimum effective dose equivalences. People with lived experience of dementia care contributed throughout this project, shaping the research question and advising on interpretation and dissemination strategies. FINDINGS: In our dataset search, we identified 108 910 people with a record indicating dementia at any time. In total, 99 091 cases were excluded (ie, individuals with no antipsychotic prescription between the ages of 60 and 85 years between 2000 and 2023, a previous history of antipsychotics, missing deprivation information, or only one eligible prescription). We included 9819 people living with dementia aged 60-85 years who received their first antipsychotic prescription between 2000 and 2023 in the study. 5310 (54·1%) were female and 4509 (45·9%) were male, with a mean age of 77·1 years (SD 5·6 years), and ethnicity data were not available. The first treatment episode lasted a median of 7 months (IQR 6·6-8·7), exceeding NICE guidelines of 1-3 months and 18·1% [95% CI 17·4-18·9]) were initiated on a prescription above the minimum effective dose (ie, low dose). Of the 1781 participants who started on a moderate or high dose, 519 (29·1%) had a moderate or high dose in all quarters of the first year of treatment. 1 year after treatment initiation, 5136 (78·3%) of 6559 eligible individuals remained on medication (48·9% [95% CI 47·7-50·1] on low dose, 14·8% [13·9-15·6] on moderate or high dose of haloperidol, olanzapine, quetiapine or risperidone; and 14·6% [13·8-15·5] on other antipsychotics). Of the 5547 individuals eligible to restart treatment after initial discontinuation, 3106 (56%) restarted with a median treatment duration of 2·6 months (IQR 0·0-9·9). INTERPRETATION: This study highlights how antipsychotic prescribing in dementia is discordant with current NICE guidelines on both duration and dose. More than half of those who discontinued their treatment then restarted treatment. These findings emphasise a persistent gap between clinical guidelines and real-world prescribing, underscoring the need for interventions that prioritise safety and person-centred dementia care. FUNDING: National Institute for Health and Care Research School for Primary Care Research.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Smith HC, Petersen I, Hayes JF, et al. Antipsychotic prescriptions in people with dementia in primary care: a cohort study investigating adherence of dose and duration to UK clinical guidelines. Lancet Psychiatry. 2025. PMID: 40967729. doi:10.1016/S2215-0366(25)00261-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。